Keen Vision Acquisition Corporation
OOTC:KVACF12.07
USD
-0.07
(-0.58%)
CIK
1889983
ISIN
VGG524431191
CUSIP
G52443119
Return %
Stock
S&P 500
1Y
3.60
14.20
3Y
18.10
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Kenneth Ka Chun Wong
- Full Time Employees
- 2
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Summit United States
- IPO Date
- Jul 25, 2023
- CIK
- 0001889983
- Website
- kv-ac.com
- Similar Companies
- Business
- Keen Vision Acquisition Corporation operates as a blank check and special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more operating enterprises. The company provides capital deployment vehicles and merger-facilitation solutions, offering products and services that include equity investment units; ordinary shares; redeemable warrants; capital aggregation and trust account management; target screening, valuation, and due diligence; transaction structuring and strategic advisory; and public market transition and merger execution services. Keen Vision Acquisition Corporation primarily targets growth-stage commercial enterprises across high-growth sectors, with a strategic focus on biotechnology, healthcare, life sciences, and technology industries across North America and international markets. Founded in 2021 as a Cayman Islands exempted company, Keen Vision Acquisition Corporation maintains its principal executive offices in Summit, New Jersey. In recent corporate developments, the company entered into a definitive merger agreement with clinical-stage biopharmaceutical developer Medera Inc. at an enterprise value of approximately $622.6 million, which was subsequently terminated in favor of a binding letter of intent to negotiate an alternative transaction centered on Medera's cellular engineering subsidiary, Novoheart. Furthermore, the company enacted amendments to its investment management trust agreement to facilitate operational extensions, and following the conclusion of its exchange-mandated combination window, its units, shares, and warrants transitioned from the Nasdaq Global Market to over-the-counter trading under the ticker symbol KVACF.